key: cord-0738085-l0kmv9cj
authors: Long, Clayton V.; Clemente, Jonathan D.; Singh, Sam; Strong, Dale; Rhoten, Jeremy B.; Prasad, Tanushree; Asimos, Andrew W.
title: Brain venography performance following the pause of Ad.26.COV2.S COVID-19 vaccine administration
date: 2021-11-05
journal: J Thromb Thrombolysis
DOI: 10.1007/s11239-021-02592-3
sha: 9a02c788a13fa13203de8aca833858b84a8c9b13
doc_id: 738085
cord_uid: l0kmv9cj

Cases of cerebral venous thrombosis (CVT) associated with vaccine induced thrombotic thrombocytopenia (VITT) were reported following administration of the adenoviral vector COVID-19 vaccines, resulting in a pause in Ad.26.COV2.S vaccine administration in the United States, beginning on April 14, 2021. We aimed to quantify and characterize an anticipated increase in brain venograms performed in response to this pause. Brain venogram cases were retrospectively identified during the three-week period following the vaccine pause and during the same calendar period in 2019. For venograms performed in 2021, we compared COVID vaccinated to unvaccinated patients. There was a 262% increase in venograms performed between 2019 (n = 26) and 2021 (n = 94), compared to only a 19% increase in all radiologic studies. Fifty-seven percent of patients in 2021 had a history of COVID-19 vaccination, with the majority being Ad.26.COV2.S. All patients diagnosed with CVT were unvaccinated. COVID vaccinated patients lacked platelet or D-dimer measurements consistent with VITT. Significantly more vaccinated versus unvaccinated patients had a headache (94% vs 70%, p = 0.0014), but otherwise lacked compelling CVT presentations, such as decreased/altered consciousness (7% vs 23%, p = 0.036), neurologic deficit (28% vs 48%, p = 0.049), and current/recent pregnancy (2% vs 28%, p = 0.0003). We found a dramatic increase in brain venograms performed following publicity of rare COVID-19 vaccine associated CVT cases, with no CVTs identified in vaccinated patients. Clinicians should carefully consider if brain venogram performance is indicated in COVID-19 vaccinated patients lacking thrombocytopenia and D-dimer elevation, especially without other compelling CVT risk factors or symptoms.

• A dramatic increase in venogram performance occurred during the three-week period following the 2021 pause in Ad.26.COV2.S COVID-19 vaccine administration compared to the same period in 2019. • The majority of patients undergoing venography had a history of COVID-19 vaccination, most of whom had received the Ad.26.COV2.S vaccine. • All patients diagnosed with CVT following the vaccine pause were unvaccinated. • Only one patient undergoing venography was thrombocytopenic and a small minority of patients had a D-dimer performed, with no patients meeting laboratory criteria for VITT. • This study suggests that the observed increase in venogram utilization occurred in a population at low risk for

In April 2021, several cases of cerebral venous thrombosis (CVT) were reported following administration of the Ad.26.COV2.S COVID-19 vaccine (Janssen Biotech, Inc., a Janssen Pharmaceutical company, Johnson & Johnson) and ChAdOx1 nCoV-19 vaccine (Oxford/AstraZeneca) [1] [2] [3] . As a result, on April 14, 2021, the U.S. Food and Drug Administration (FDA) and U.S. Centers for Disease Control and Prevention (CDC) announced a "pause" in the use of the single-dose Ad.26.COV2.S vaccine while an investigation was conducted into the rare reports of CVT [4, 5] . As of April 14th, our large healthcare system had administered approximately 18,500 doses of the Ad.26.COV2.S vaccine, while over 6.8 million doses had been administered throughout the U.S [6] . Because of the widespread attention the rare CVT events received, and because CVT can be challenging to diagnose clinically [7, 8] , we sought to quantify and characterize the patients undergoing brain venography to evaluate for CVT in the three weeks immediately following this announcement.

To determine the difference in brain venogram utilization following the pause compared to historical cohorts, the total number of venograms performed from April 14 to May 5 in 2019 (pre-pandemic) and 2020 (pandemic) were compared to the same three-week period in 2021. The 2021 cohort was divided into vaccinated versus unvaccinated patients for comparative analyses. Cases were identified in a retrospective cross-sectional manner based on the inclusion criteria of age 18 and older who had a computed tomography brain venogram (CTV) or magnetic resonance brain venogram (MRV) performed at one of our healthcare system's 12 hospitals, 7 free-standing emergency departments, and 7 outpatient imaging centers, covering a region with a population of approximately 1.9 million people. Patients less than 18 years of age and any patient with health records not accessible via our electronic medical record (EMR) were excluded from the study. We additionally excluded patients who had a repeat venogram performed to assess progression or resolution of a previously diagnosed CVT. Individual cases were identified by querying the radiology report database (Primordial, Prism, Nuance Communications, Burlington, MA) for our healthcare system. Keyword search of the radiology reports was employed using the following keywords: venogram, venography, CTV, MRV, venous sinus thrombosis, venous sinus thrombus. Data abstracted from our EMR included patient demographics, CVT symptoms, CVT risk factors, comorbidities, radiologic evaluation, and additional nonimaging diagnostic workup. Vaccination status was verified by accessing an enterprise data warehouse, which facilitated capturing the vaccination record for patients vaccinated outside our healthcare system. We analyzed data with standard statistical methods utilizing the SAS program version 9.4 (SAS, Cary, NC, USA 

There was a 262% increase in the number of venograms performed when comparing the same three-week period from 2021 (n = 94) following the vaccine pause to 2019 (n = 26 

Our data suggest that during the same three-week period in 2019, 2020, and 2021 that trends in venogram utilization likely resulted from the reported rare risk of CVT associated with COVID-19 vaccination, and not from the risk of CVT associated with COVID infection. Moreover, the increased venogram utilization in vaccinated patients appears to have been in a population at overall low risk for CVT, because they lacked compelling symptoms for CVT (beyond headache), lacked prothrombotic risk factors or other comorbidities predisposing to CVT, and lacked laboratory findings consistent with VITT. Given the dramatic increase we found in venograms performed within just one healthcare system that was associated with the extensive publicity of rare CVT cases in the setting of VITT, it is likely venogram utilization increased in other settings as well. Moving forward, clinicians should carefully consider if performance of a venogram is indicated in adenoviral vector COVID-19 vaccinated individuals, in the absence of thrombocytopenia and D-dimer elevation, especially without other compelling CVT risk factors or symptoms.

Funding None.

Data availability Data available within the article or its supplementary material.

Code availability Not applicable.

Conflict of interest None.

Ethical approval Electronic medical record access approved by institutional review board.

Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination

Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination

Thrombotic thrombocytopenia after Ad26.COV2.S vaccination

CDC Health Alert Network. Cases of Cerebral Venous Sinus Thrombosis with Thrombocytopenia after Receipt of the Johnson & Johnson COVID-19 Vaccine

Thrombotic thrombocytopenia after Ad26.COV2.S vaccination-response from the manufacturer

Safety monitoring of the Janssen (Johnson & Johnson) COVID-19 vaccine-United States

Cerebral venous thrombosis: a comprehensive review

Cerebral venous sinus thrombosis